Pfizer’s Foes in Bench Trial Over Vyndamax Copies Down to Hikma

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench ...

Pfizer’s Deal With Hikma Ends Patent Trial on Vyndamax Copy (1)

Pfizer Inc. agreed to end a dispute with Hikma Pharmaceuticals Plc after one day of trial, resolving the last remaining ...
Hosted on MSN

Pfizer’s long-awaited Lyme vaccine fails to impress in study

(Bloomberg) -- Pfizer Inc. said its experimental Lyme disease vaccine was 73% effective against the tick-borne illness, a lackluster result as fewer-than-expected infections in the pivotal study made ...
RAPS

Recon: FDA approves Merck’s Keytruda for advanced endometrial cancer; Pfizer recalls some BP drug lots due to nitrosamine impurity

Pfizer, Abbott Labs, AbbVie Legal Chiefs Get Big Pharma Paydays (Bloomberg) With midphase data in hand, MediPrint lands investment to take drug delivery contact lens deeper into the clinic (Fierce) ...
RAPS

Recon: US signs $3.2B deal for Pfizer-BioNTech vaccines; Novartis said to lean toward spinoff of generics unit

Recon: US signs $3.2B deal for Pfizer-BioNTech vaccines; Novartis said to lean toward spinoff of generics unit Welcome to Regulatory Reconnaissance, your daily regulatory news and intelligence ...